{"id":"W4288045904","doi":"10.1016/j.ijcard.2022.07.017","title":"Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group","year":2022,"lang":"en","type":"article","venue":"International Journal of Cardiology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Bausch Health; Mylan; Kowa Company; Novo Nordisk; Sanofi; AstraZeneca; Eli Lilly and Company; Servier; Amgen","keywords":"Medicine; Liraglutide; Dulaglutide; Semaglutide; Glucagon-like peptide 1 receptor; Incretin; Glucagon-like peptide-1; Type 2 Diabetes Mellitus; Internal medicine; Clinical trial; Type 2 diabetes; Diabetes mellitus; Exenatide; Endocrinology; Receptor; Agonist","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003940772,0.0001911823,0.001029785,0.00009994749,0.0001443698,0.0000696618,0.0003273545,0.00005441224,0.00008013983],"category_scores_gemma":[0.001906722,0.0001157381,0.0006336612,0.00008021828,0.000115532,0.0001640601,0.000179619,0.0004290796,0.00001243919],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009896739,"about_ca_system_score_gemma":0.00008706948,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002288178,"about_ca_topic_score_gemma":0.00001237253,"domain_scores_codex":[0.9958215,0.001799463,0.001174677,0.0003139819,0.000721065,0.0001692904],"domain_scores_gemma":[0.995088,0.003339522,0.0007988184,0.0003055926,0.0003689975,0.0000990538],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.009350245,0.0005574637,0.3393836,0.000008762234,0.09735537,0.0008536008,0.009876204,0.0007551777,0.0006498311,0.0001160755,0.02321262,0.5178811],"study_design_scores_gemma":[0.01243513,0.001153683,0.02301691,0.0001252815,0.002427986,0.00007008824,0.005215293,0.00008896244,0.00001666128,0.0001607353,0.9551038,0.0001855005],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8948835,0.007471472,0.002820338,0.08662511,0.005401956,0.0006729856,0.0005559981,0.00003701568,0.001531698],"genre_scores_gemma":[0.9819576,0.001259731,0.009908431,0.003490824,0.002499512,0.00005380736,0.000531212,0.0000404981,0.0002584347],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9318911,"threshold_uncertainty_score":0.4719664,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05594745286082843,"score_gpt":0.3558025854240979,"score_spread":0.2998551325632695,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}